Connect with us

Kate O

  •   Pharmaceutical company GSK has been awarded a contract to produce the world s first malaria vaccine so that millions more children are protected against the deadly disease the United Nations Children s Fund UNICEF announced on Tuesday The landmark award valued at up to 170 million will result in 18 million doses of the RTS S vaccine being made available over the next three years potentially saving the lives of thousands of young people each year Malaria remains one of the leading causes of death for children under the age of five In 2020 almost half a million children died from the disease in Africa alone at a rate of one death per minute Etleva Kadilli UNICEF Supply Division Director said the launch sends a clear message to malaria vaccine developers to continue their work We hope this is just the beginning Continued innovation is needed to develop new and next generation vaccines to increase the available supply and enable a healthier vaccine market she said This is a major step forward in our collective efforts to save children s lives and reduce the burden of malaria as part of broader malaria prevention and control programs Preventable disease Malaria is caused by parasites and is transmitted to humans through infected female Anopheles mosquitoes While the disease is preventable and curable it can be fatal if left untreated More than 30 countries have areas with moderate to high malaria transmission according to data from the World Health Organization WHOOpens in a new window and the vaccine could provide additional protection to more than 25 million children each year a once the supply increases The RTS S malaria vaccine the result of 35 years of research and development is the first vaccine against a parasitic disease Pilot program It was launched in a 2019 pilot program coordinated by the WHO in three countries Ghana Kenya and Malawi which has reached more than 800 000 children Last October the UN health agency recommended Opens in new window for widespread use in countries with moderate to high malaria transmission That December Gavi the Vaccine Alliance made the decision to provide funding for malaria vaccine programs in eligible countries thus paving the way for broader implementation of the vaccine Funding window opened CEO Seth Barkley reported that Gavi recently opened the application window for funding requests Thanks to UNICEF s procurement work we now have more certainty about supply and can go one step further in getting this life saving vaccine to the people who need it most As manufacturing increases over time we expect that increased volumes will also lead to lower and more sustainable prices he said Meanwhile the WHO has welcomed progress in ensuring timely supply and access to the vaccine so that more countries can introduce it as soon as possible Lives are at stake every day said Dr Kate O Brien director of WHO s Department of Immunization Vaccines and Biologicals Given the limited initial supply it is crucial that children who live in areas where disease risk and need are highest are prioritized first High demand expected UNICEF expects demand for the malaria vaccine to be high among affected countries As with any new vaccine supply will be limited at first the agency said but will increase as manufacturing capacity increases over time which in turn will lead to lower costs per dose Plans are already underway to boost production including through technology transfer UNICEF added so that every child at risk will one day have a chance to be immunized against this deadly disease
    Millions more children to benefit from world’s first malaria vaccine: United Nations Children’s International Emergency Fund (UNICEF)
      Pharmaceutical company GSK has been awarded a contract to produce the world s first malaria vaccine so that millions more children are protected against the deadly disease the United Nations Children s Fund UNICEF announced on Tuesday The landmark award valued at up to 170 million will result in 18 million doses of the RTS S vaccine being made available over the next three years potentially saving the lives of thousands of young people each year Malaria remains one of the leading causes of death for children under the age of five In 2020 almost half a million children died from the disease in Africa alone at a rate of one death per minute Etleva Kadilli UNICEF Supply Division Director said the launch sends a clear message to malaria vaccine developers to continue their work We hope this is just the beginning Continued innovation is needed to develop new and next generation vaccines to increase the available supply and enable a healthier vaccine market she said This is a major step forward in our collective efforts to save children s lives and reduce the burden of malaria as part of broader malaria prevention and control programs Preventable disease Malaria is caused by parasites and is transmitted to humans through infected female Anopheles mosquitoes While the disease is preventable and curable it can be fatal if left untreated More than 30 countries have areas with moderate to high malaria transmission according to data from the World Health Organization WHOOpens in a new window and the vaccine could provide additional protection to more than 25 million children each year a once the supply increases The RTS S malaria vaccine the result of 35 years of research and development is the first vaccine against a parasitic disease Pilot program It was launched in a 2019 pilot program coordinated by the WHO in three countries Ghana Kenya and Malawi which has reached more than 800 000 children Last October the UN health agency recommended Opens in new window for widespread use in countries with moderate to high malaria transmission That December Gavi the Vaccine Alliance made the decision to provide funding for malaria vaccine programs in eligible countries thus paving the way for broader implementation of the vaccine Funding window opened CEO Seth Barkley reported that Gavi recently opened the application window for funding requests Thanks to UNICEF s procurement work we now have more certainty about supply and can go one step further in getting this life saving vaccine to the people who need it most As manufacturing increases over time we expect that increased volumes will also lead to lower and more sustainable prices he said Meanwhile the WHO has welcomed progress in ensuring timely supply and access to the vaccine so that more countries can introduce it as soon as possible Lives are at stake every day said Dr Kate O Brien director of WHO s Department of Immunization Vaccines and Biologicals Given the limited initial supply it is crucial that children who live in areas where disease risk and need are highest are prioritized first High demand expected UNICEF expects demand for the malaria vaccine to be high among affected countries As with any new vaccine supply will be limited at first the agency said but will increase as manufacturing capacity increases over time which in turn will lead to lower costs per dose Plans are already underway to boost production including through technology transfer UNICEF added so that every child at risk will one day have a chance to be immunized against this deadly disease
    Millions more children to benefit from world’s first malaria vaccine: United Nations Children’s International Emergency Fund (UNICEF)
    Africa4 months ago

    Millions more children to benefit from world’s first malaria vaccine: United Nations Children’s International Emergency Fund (UNICEF)

    Pharmaceutical company GSK has been awarded a contract to produce the world's first malaria vaccine so that millions more children are protected against the deadly disease, the United Nations Children's Fund (UNICEF) announced on Tuesday.

    The landmark award, valued at up to $170 million, will result in 18 million doses of the RTS,S vaccine being made available over the next three years, potentially saving the lives of thousands of young people each year.

    Malaria remains one of the leading causes of death for children under the age of five.

    In 2020, almost half a million children died from the disease in Africa alone, at a rate of one death per minute.

    Etleva Kadilli, UNICEF Supply Division Director, said the launch sends a clear message to malaria vaccine developers to continue their work.

    “We hope this is just the beginning.

    Continued innovation is needed to develop new and next-generation vaccines to increase the available supply and enable a healthier vaccine market,” she said.

    "This is a major step forward in our collective efforts to save children's lives and reduce the burden of malaria as part of broader malaria prevention and control programs."

    Preventable disease Malaria is caused by parasites and is transmitted to humans through infected female Anopheles mosquitoes.

    While the disease is preventable and curable, it can be fatal if left untreated.

    More than 30 countries have areas with moderate to high malaria transmission, according to data from the World Health Organization (WHOOpens in a new window), and the vaccine could provide additional protection to more than 25 million children each year a once the supply increases.

    The RTS,S malaria vaccine, the result of 35 years of research and development, is the first vaccine against a parasitic disease.

    Pilot program It was launched in a 2019 pilot program, coordinated by the WHO, in three countries - Ghana, Kenya and Malawi - which has reached more than 800,000 children.

    Last October, the UN health agency recommended Opens in new window for widespread use in countries with moderate to high malaria transmission.

    That December, Gavi, the Vaccine Alliance, made the decision to provide funding for malaria vaccine programs in eligible countries, thus paving the way for broader implementation of the vaccine.

    Funding 'window' opened CEO Seth Barkley reported that Gavi recently opened the 'application window' for funding requests.

    “Thanks to UNICEF's procurement work, we now have more certainty about supply and can go one step further in getting this life-saving vaccine to the people who need it most.

    As manufacturing increases over time, we expect that increased volumes will also lead to lower and more sustainable prices,” he said.

    Meanwhile, the WHO has welcomed progress in ensuring timely supply and access to the vaccine so that more countries can introduce it as soon as possible.

    “Lives are at stake every day,” said Dr. Kate O'Brien, director of WHO's Department of Immunization, Vaccines and Biologicals.

    “Given the limited initial supply, it is crucial that children who live in areas where disease risk and need are highest are prioritized first.” High demand expected UNICEF expects demand for the malaria vaccine to be high among affected countries.

    As with any new vaccine, supply will be limited at first, the agency said, but will increase as manufacturing capacity increases over time, which in turn will lead to lower costs per dose.

    Plans are already underway to boost production, including through technology transfer, UNICEF added, "so that every child at risk will one day have a chance to be immunized against this deadly disease."

  •   UNICEF awards 170m malaria vaccine contracUnited Nations Children s Fund UNICEF has awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to 170 million dollars The News Agency of Nigeria reports that GSK plc formerly GlaxoSmithKline plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London England Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham UNICEF in a statement issued from New York on Tuesday said the landmark award would lead to 18 million doses of RTS 01 RTS S being available over the next three years potentially saving thousands of lives every year In 2020 nearly half a million children died from malaria in Africa alone a rate of one child death per minute Etleva Kadilli Director of UNICEF s Supply Division said the vaccine rollout would give a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted We hope this is just the beginning Continued innovation is needed to develop new and next generation vaccines to increase available supply and enable a healthier vaccine market This is a giant step forward in our collective efforts to save children s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes According to WHO data more than 30 countries have areas with moderate to high malaria transmission where the vaccine could provide added protection against malaria to over 25 million children each year once supply scales up The RTS S malaria vaccine is the result of 35 years of research and development and is the first ever vaccine against a parasitic disease The vaccine acts against Plasmodium falciparum the most deadly malaria parasite globally and the most prevalent in Africa In 2019 pilot routine vaccine use was launched in three countries Ghana Kenya and Malawi as part of the Malaria Vaccine Implementation Programme coordinated by WHO The experience and evidence generated by the pilots informed WHO s recommendation in October 2021 for widespread use of the first malaria vaccine in countries with moderate to high P falciparum malaria transmission Soon after in December 2021 Gavi the Vaccine Alliance s decision to provide funding for malaria vaccine programmes in eligible countries opened the pathway for broader roll out of the vaccine We recently opened the first application window for Gavi support in rolling out the malaria vaccine Thanks to UNICEF s procurement work we now have more certainty on supply and can move a step further towards getting this life saving vaccine to the people who need it the most As manufacturing ramps up over time we hope that increasing volumes will also lead to more sustainable lower prices Seth Berkley CEO of Gavi the Vaccine Alliance said Dr Kate O Brien WHO Director of the Department of Immunisation Vaccines and Biologicals said lives are at stake every day WHO welcomes the progress to secure supply and timely access to vaccine so that more countries can begin to introduce this additional malaria prevention tool as rapidly as possible Given the initial limited supply it is crucial that children living in areas where the risk of disease and need is highest are prioritised first This award is the culmination of 18 months of intensive preparation and consultation with industry and partners As the largest buyer of vaccines in the world UNICEF accelerated action to conclude procurement negotiations to ensure there are no delays in securing available supplies of the malaria vaccine to help protect vulnerable children Demand for the malaria vaccine is expected to be high among affected countries As with any new vaccine supply will be limited at first and will increase over time as manufacturing capacity ramps up to the level required As volumes increase costs per dose should decrease Plans are already underway to boost production including through technology transfer so that every child at risk will one day have the opportunity to be immunized against this killer disease We must not lose sight of the need to accelerate access to this and future malaria vaccines and to make the necessary investments in malaria control and immunization services as well as in research and development Effective malaria and immunization programs are both key to the successful delivery of a malaria vaccine and contribute to stronger health systems overall Dr Ashley Birkett Global Head of Malaria Vaccines and Biologics at PATH said UNICEF supports the regional diversification of vaccine production and encourages GSK and other pipeline manufacturers to consider partnering with companies in Africa as part of this effort www nannews ng NewsSourceCredit NAN
    UNICEF awards 0m malaria vaccine contract to GSK
      UNICEF awards 170m malaria vaccine contracUnited Nations Children s Fund UNICEF has awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to 170 million dollars The News Agency of Nigeria reports that GSK plc formerly GlaxoSmithKline plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London England Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham UNICEF in a statement issued from New York on Tuesday said the landmark award would lead to 18 million doses of RTS 01 RTS S being available over the next three years potentially saving thousands of lives every year In 2020 nearly half a million children died from malaria in Africa alone a rate of one child death per minute Etleva Kadilli Director of UNICEF s Supply Division said the vaccine rollout would give a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted We hope this is just the beginning Continued innovation is needed to develop new and next generation vaccines to increase available supply and enable a healthier vaccine market This is a giant step forward in our collective efforts to save children s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes According to WHO data more than 30 countries have areas with moderate to high malaria transmission where the vaccine could provide added protection against malaria to over 25 million children each year once supply scales up The RTS S malaria vaccine is the result of 35 years of research and development and is the first ever vaccine against a parasitic disease The vaccine acts against Plasmodium falciparum the most deadly malaria parasite globally and the most prevalent in Africa In 2019 pilot routine vaccine use was launched in three countries Ghana Kenya and Malawi as part of the Malaria Vaccine Implementation Programme coordinated by WHO The experience and evidence generated by the pilots informed WHO s recommendation in October 2021 for widespread use of the first malaria vaccine in countries with moderate to high P falciparum malaria transmission Soon after in December 2021 Gavi the Vaccine Alliance s decision to provide funding for malaria vaccine programmes in eligible countries opened the pathway for broader roll out of the vaccine We recently opened the first application window for Gavi support in rolling out the malaria vaccine Thanks to UNICEF s procurement work we now have more certainty on supply and can move a step further towards getting this life saving vaccine to the people who need it the most As manufacturing ramps up over time we hope that increasing volumes will also lead to more sustainable lower prices Seth Berkley CEO of Gavi the Vaccine Alliance said Dr Kate O Brien WHO Director of the Department of Immunisation Vaccines and Biologicals said lives are at stake every day WHO welcomes the progress to secure supply and timely access to vaccine so that more countries can begin to introduce this additional malaria prevention tool as rapidly as possible Given the initial limited supply it is crucial that children living in areas where the risk of disease and need is highest are prioritised first This award is the culmination of 18 months of intensive preparation and consultation with industry and partners As the largest buyer of vaccines in the world UNICEF accelerated action to conclude procurement negotiations to ensure there are no delays in securing available supplies of the malaria vaccine to help protect vulnerable children Demand for the malaria vaccine is expected to be high among affected countries As with any new vaccine supply will be limited at first and will increase over time as manufacturing capacity ramps up to the level required As volumes increase costs per dose should decrease Plans are already underway to boost production including through technology transfer so that every child at risk will one day have the opportunity to be immunized against this killer disease We must not lose sight of the need to accelerate access to this and future malaria vaccines and to make the necessary investments in malaria control and immunization services as well as in research and development Effective malaria and immunization programs are both key to the successful delivery of a malaria vaccine and contribute to stronger health systems overall Dr Ashley Birkett Global Head of Malaria Vaccines and Biologics at PATH said UNICEF supports the regional diversification of vaccine production and encourages GSK and other pipeline manufacturers to consider partnering with companies in Africa as part of this effort www nannews ng NewsSourceCredit NAN
    UNICEF awards 0m malaria vaccine contract to GSK
    Foreign4 months ago

    UNICEF awards $170m malaria vaccine contract to GSK

    UNICEF awards $170m malaria vaccine contracUnited Nations Children’s Fund (UNICEF) has awarded a contract for the first ever supply of a malaria vaccine to GSK with a value of up to 170 million dollars.

    The News Agency of Nigeria reports that GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.

    Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham.

    UNICEF in a statement issued from New York on Tuesday said the landmark award would lead to 18 million doses of RTS,01 (RTS,S) being available over the next three years, potentially saving thousands of lives every year.

    In 2020, nearly half a million children died from malaria in Africa alone, a rate of one child death per minute.

    Etleva Kadilli, Director of UNICEF’s Supply Division said the vaccine rollout would give a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted.

    “We hope this is just the beginning.

    Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market.

    “This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.

    ” According to WHO data, more than 30 countries have areas with moderate to high malaria transmission, where the vaccine could provide added protection against malaria to over 25 million children each year once supply scales up.

    The RTS,S malaria vaccine is the result of 35 years of research and development and is the first-ever vaccine against a parasitic disease.

    The vaccine acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa.

    In 2019, pilot routine vaccine use was launched in three countries – Ghana, Kenya and Malawi – as part of the Malaria Vaccine Implementation Programme coordinated by WHO.

    The experience and evidence generated by the pilots informed WHO’s recommendation in October 2021 for widespread use of the first malaria vaccine in countries with moderate to high P.

    falciparum malaria transmission.

    Soon after, in December 2021, Gavi, the Vaccine Alliance’s decision to provide funding for malaria vaccine programmes in eligible countries opened the pathway for broader roll-out of the vaccine.

    “We recently opened the first application window for Gavi support in rolling out the malaria vaccine.

    “Thanks to UNICEF’s procurement work, we now have more certainty on supply and can move a step further towards getting this life-saving vaccine to the people who need it the most.

    “As manufacturing ramps up over time, we hope that increasing volumes will also lead to more sustainable, lower prices,” Seth Berkley, CEO of Gavi, the Vaccine Alliance, said.

    Dr Kate O’Brien, WHO Director of the Department of Immunisation, Vaccines and Biologicals said lives are at stake, every day.

    “WHO welcomes the progress to secure supply and timely access to vaccine so that more countries can begin to introduce this additional malaria prevention tool as rapidly as possible.

    “Given the initial limited supply, it is crucial that children living in areas where the risk of disease and need is highest are prioritised first.

    ” This award is the culmination of 18 months of intensive preparation and consultation with industry and partners.

    As the largest buyer of vaccines in the world, UNICEF accelerated action to conclude procurement negotiations, to ensure there are no delays in securing available supplies of the malaria vaccine to help protect vulnerable children.

    Demand for the malaria vaccine is expected to be high among affected countries.

    As with any new vaccine, supply will be limited at first and will increase over time as manufacturing capacity ramps up to the level required.

    As volumes increase, costs per dose should decrease.

    Plans are already underway to boost production, including through technology transfer, so that every child at risk will one day have the opportunity to be immunized against this killer disease.

    “We must not lose sight of the need to accelerate access to this and future malaria vaccines, and to make the necessary investments in malaria control and immunization services, as well as in research and development.

    “Effective malaria and immunization programs are both key to the successful delivery of a malaria vaccine and contribute to stronger health systems overall,” Dr Ashley Birkett, Global Head of Malaria Vaccines and Biologics at PATH, said.

    UNICEF supports the regional diversification of vaccine production and encourages GSK and other pipeline manufacturers to consider partnering with companies in Africa as part of this effort.

    (www.

    nannews.

    ng)
    NewsSourceCredit: NAN

latest nigerian news headlines bat9ja shop saharahausa link shortners Soundcloud downloader